Latest News News

The IIDR & DBCAD are proud to announce our 2022 cohort of seed funding recipients!

Since its establishment in 2007, the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) has been active in providing seed funding for new collaborations and high-risk projects focused around the overarching themes of anti-infective innovation, diagnostics, and laboratory and clinical collaboration. Committed to helping eliminate the global threat of antimicrobial resistance, the David Braley Centre for Antibiotic Discovery (DBCAD) has further demonstrated its commitment to fostering scientific collaboration by providing significant seed funding for milestone-driven projects related to antimicrobial research and discovery.

The purpose of these funding initiatives is to provide opportunities for IIDR & DBCAD members to work collaboratively and creatively. The funding provides support for trainees that are essential for the project and operating funds to help members generate preliminary data and provide evidence for collaboration that will enable them to secure additional funding from other agencies.

Following a review of submitted research proposals, the IIDR and DBCAD are pleased to announce this year’s research funding recipients and renewals. Congratulations! Details about this year’s funded projects are below.

Author:

Blake Dillon